BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32941706)

  • 1. Longitudinal analysis of complete blood count parameters in advanced-stage lung cancer patients.
    Rojko L; Megyesfalvi Z; Czibula E; Reiniger L; Teglasi V; Szegedi Z; Szallasi Z; Dome B; Moldvay J
    Thorac Cancer; 2020 Nov; 11(11):3193-3204. PubMed ID: 32941706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
    Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
    J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of risk factors and gene mutation characteristics of different metastatic sites of lung cancer.
    Wang B; Chen S; Xiao H; Zhang J; Liang D; Shan J; Zou H
    Cancer Med; 2022 Jan; 11(1):268-280. PubMed ID: 34799997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer.
    Shoji F; Kozuma Y; Toyokawa G; Yamazaki K; Takeo S
    Ann Thorac Cardiovasc Surg; 2020 Oct; 26(5):248-255. PubMed ID: 32074540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CyberKnife Radiosurgery on Overall Survival and Various Parameters of Patients with 1-3 versus ≥ 4 Brain Metastases.
    Murovic J; Ding V; Han SS; Adler JR; Chang SD
    Cureus; 2017 Oct; 9(10):e1798. PubMed ID: 29282442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic markers of distant metastases and poor prognosis in gynecological cancers.
    Abu-Shawer O; Abu-Shawer M; Hirmas N; Alhouri A; Massad A; Alsibai B; Sultan H; Hammo H; Souleiman M; Shebli Y; Al-Hussaini M
    BMC Cancer; 2019 Feb; 19(1):141. PubMed ID: 30755184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Tanizaki J; Haratani K; Hayashi H; Chiba Y; Nakamura Y; Yonesaka K; Kudo K; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Ito A; Nakagawa K
    J Thorac Oncol; 2018 Jan; 13(1):97-105. PubMed ID: 29170120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy.
    Joseph N; McWilliam A; Kennedy J; Haslett K; Mahil J; Gavarraju A; Mistry H; Van Herk M; Faivre-Finn C; Choudhury A
    Radiother Oncol; 2019 Jun; 135():115-119. PubMed ID: 31015156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
    Sert F; Cosgun G; Yalman D; Ozkok S
    Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study.
    Karantanos T; Karanika S; Seth B; Gignac G
    Clin Transl Oncol; 2019 Feb; 21(2):206-212. PubMed ID: 29948974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of peripheral immune cell counts in pancreatic cancer.
    Abu-Shawer O; Abu-Shawer M; Shurman A; Lattouf A; Haimour A; Hamdan O; Mansour R; Altamimi T; Al-Hussaini M
    PLoS One; 2020; 15(6):e0232043. PubMed ID: 32542007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of D-dimer in lung cancer.
    İnal T; Anar C; Polat G; Ünsal İ; Halilçolar H
    Clin Respir J; 2015 Jul; 9(3):305-13. PubMed ID: 24720709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
    Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
    Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
    Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
    PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective evaluation of associations between chronic obstructive pulmonary disease, smoking, and efficacy of chemotherapy and selected laboratory parameters in patients with advanced non-small cell lung cancer.
    Czyżykowski R; Nowak D; Janiak A; Włodarczyk A; Sarniak A; Krakowska M; Potemski P
    Contemp Oncol (Pozn); 2016; 20(5):407-413. PubMed ID: 28373824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
    Zer A; Sung MR; Walia P; Khoja L; Maganti M; Labbe C; Shepherd FA; Bradbury PA; Feld R; Liu G; Iazzi M; Zawisza D; Nouriany N; Leighl NB
    Clin Lung Cancer; 2018 Sep; 19(5):426-434.e1. PubMed ID: 29803574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of haematologic parameter changes during treatment in cervical cancer patients treated with definitive chemoradiotherapy.
    Yildirim BA; Guler OC; Kose F; Onal C
    J Obstet Gynaecol; 2019 Jul; 39(5):695-701. PubMed ID: 31023114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection.
    Jeong E; Hyun SH; Moon SH; Cho YS; Kim BT; Lee KH
    Medicine (Baltimore); 2017 Feb; 96(5):e5935. PubMed ID: 28151879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the factors associated with abnormal coagulation and prognosis
 in patients with non-small cell lung cancer].
    Li Y; Wei S; Wang J; Hong L; Cui L; Wang C
    Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):789-96. PubMed ID: 25404269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.